Cue Biopharma Files 8-K on Bylaw Amendments

Ticker: CUE · Form: 8-K · Filed: Apr 22, 2026 · CIK: 0001645460

Sentiment: neutral

Topics: corporate-governance, bylaws, amendment

TL;DR

Cue Biopharma just filed an 8-K for bylaw changes - could be big.

AI Summary

On April 22, 2026, Cue Biopharma, Inc. filed an 8-K report detailing amendments to its Articles of Incorporation or Bylaws. This filing indicates potential changes to the company's governance or operational structure, as outlined in Item 5.03.

Why It Matters

Amendments to a company's articles of incorporation or bylaws can signal significant shifts in corporate governance, operational strategy, or shareholder rights.

Risk Assessment

Risk Level: medium — Amendments to articles of incorporation or bylaws can have significant implications for the company's structure and governance, warranting closer examination.

Key Numbers

Key Players & Entities

FAQ

What specific changes were made to Cue Biopharma's Articles of Incorporation or Bylaws?

The filing indicates amendments under Item 5.03, but the specific details of these changes are not provided in the summary text and would require reviewing the attached exhibits (EX-3.1).

What is the significance of Item 3.03 in this filing?

Item 3.03 pertains to Material Modifications to Rights of Security Holders, suggesting the bylaw amendments may impact shareholder rights.

When was this 8-K filing accepted by the SEC?

The filing was accepted on April 22, 2026, at 08:47:47.

What is Cue Biopharma's state of incorporation and fiscal year end?

Cue Biopharma, Inc. is incorporated in Delaware (DE) and its fiscal year ends on December 31 (1231).

What is the SIC code for Cue Biopharma, Inc.?

The SIC code for Cue Biopharma, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on April 22, 2026 regarding Cue Biopharma, Inc. (CUE).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing